Roche Drops After Halting Cholesterol Drug Development

Roche Holding AG fell the most in almost six months in Zurich trading after abandoning development of an experimental cholesterol drug as a late-stage trial showed it wasn’t working.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.